Pharmaceuticals and Drugs (FSS-61-IB)

Award Date 3/15/1993
Last Date To Order 9/29/2103
Shared Ceiling Not listed
Contract Type
Master GSA Schedule
Predecessor
Not listed
Successors

The Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) is a master contract vehicle administered by the General Services Administration (GSA) that enables federal agencies, primarily the Department of Veterans Affairs (VA), to procure a wide range of pharmaceutical products and medical treatments. This schedule encompasses medications for various medical conditions, including treatments for rare diseases, neurological disorders, oncology, pulmonary conditions, and diagnostic imaging agents. The vehicle facilitates efficient procurement of specialized and critical pharmaceutical products through standardized contracting mechanisms, allowing federal healthcare providers to access essential medications through pre-negotiated pricing and terms.

The task orders under this vehicle are predominantly awarded to large pharmaceutical manufacturers and specialized biotechnology companies, with most contracts ranging from approximately $10,000 to $5.3 million. Frequent prime contractors include Advanced Accelerator Applications USA Inc. (a Novartis subsidiary), Progenics Pharmaceuticals, United Therapeutics, Merck, Takeda Pharmaceuticals, and Harmony Biosciences. The Department of Veterans Affairs is the primary funding agency, with most delivery orders supporting medical treatments for veterans through various Integrated Service Networks (VISNs). Contracts typically have firm fixed-pricing and performance periods ranging from several months to three years. No set-aside designations were used in the observed task orders, indicating open competition among large pharmaceutical firms. Performance locations primarily include VA medical centers across multiple states, with some contracts also serving federal correctional facilities and other government healthcare institutions.

Generated 1/16/25, 12:07 AM